 SOUTH SAN FRANCISCO, Calif., June 28, 2021 PRNewswire -- IDEAYA Biosciences, Inc. Nasdaq:IDYA, a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced updates for its Phase 1 clinical trial evaluating IDE397 in patients having solid tumors with MTAP deletion and Phase 12 clinical trial evaluating darovasertib combination therapies in metastatic uveal melanoma MUM. 